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INTRODUCTION 
“For all the happiness that man can gain 
  is not in pleasure, but in rest from pain”
- John Dryden 
Pain is the most frequent cause of suffering and disability. It is derived 
from the Latin  word “peona” meaning “punishment”  Pain is  body’s cry for 
help.
Pain is an extraordinary complex sensation which is difficult to 
define and equally difficult to measure in accurate objective manner. It is an 
unpleasant  sensory  and  emotional  experience,  associated  with  actual  or 
potential tissue damage or described in terms of such damage. Historically, the 
management of post-operative analgesia has always been plagued by lack of 
interest and enthusiasm among practitioners of anesthesia.
 “………….. a visit  to most post-operative wards will  show the time 
honored ritual of inadequate post-operative pain management. Patients expect 
ineffective post-operative pain relief and their carers ensure that they are not 
disappointed ”.
- Hammer M (Anesthesia 1991; 46:167-8)
Pain  is  a  consistent  and  predominant  complaint  of  most  individuals 
following most surgical interventions. Failure to relieve pain is ethically and 
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morally unacceptable. Adequate pain relief could be considered a basic human 
right.
Adequate treatment of post-operative pain is essential not only from a 
humanitarian  point  of  view,  but  also  from a  physiological  aspect.  Pain  has 
several detrimental effects and good postoperative pain relief helps to decrease 
postoperative morbidity and hastens recovery. It also permits early ambulation 
and reduces the duration of hospital stay.
Poorly managed acute pain can lead to the occurrence of chronic pain. 
There is high incidence of pain following limb amputation, breast surgery, gall 
bladder surgery, lung surgery or inguinal hernia repair. The severity of post-
operative  pain  following these  surgeries  is  a  potent  predictor  of  subsequent 
chronic  pain.  Even  today,  despite  many  advances  in  drugs,  devices  and 
techniques for effective delivery of perioperative pain relief, poverty of interests 
in pain relief still  continues, due to the hazards and fatal complications, that 
demand frequent visits by the physician, complex instruments that are needed to 
be set up and monitored. 
Clearly, the need of the hour is modification of the anaesthetic technique 
itself, so that it provides postoperative analgesia as well.
An ideal postoperative pain relief technique,
• Should be effective in majority of patients receiving the technique,
• Should be simple,  easy to administer and preferably a part  of the 
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anesthetic technique, 
• Should not lead to respiratory –depression,
• Should be free from motor paralysis and immobility.
In  recent  years,  there  has  been  a  shift  from the  search  for  the  more 
perfect analgesic, towards the use of more effective routes of administration and 
delivery system. This has led to the acceptance of Patient Controlled Analgesia 
& central drug administration. 
Recently, many drugs like opioids and other adjuvants have been used in 
intrathecal and epidural space for post-operative pain relief. But, side effects 
like  respiratory  depression,  pruritis,  nausea  and  vomiting  limits  usage  of 
opioids. There is also need for specialized monitoring and staffing which will 
increase the cost of health care.  
So,  many  other  drugs  have  been  tried.  There  are  around  25 
neurotransmitters  identified  in  the  spinal  cord.  One  among  them  is 
acetylcholine, which has been reported to exert antinociceptive effects. 
Hence, the present study has been undertaken to combine neostigmine an 
anticholinesterase,  which  prevents  breakdown  of  acetylcholine,  along  with 
bupivacaine for epidural administration to provide post-operative pain relief. 
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AIM OF THE STUDY
• To evaluate the efficacy of epidurally administered Neostigmine, along 
with Bupivacaine for post-operative pain relief in lower abdominal 
-surgeries.
• To evaluate the merits and demerits of Neostigmine administered 
epidurally.
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ANATOMY OF EPIDURAL SPACE
It is a potential negative space within the cranium. The endosteal and 
meningeal  layers  of  duramater  are  closely  united,  but  below  the  foramen 
magnum the two layers separate, the outer layer becoming the periosteal lining 
of spinal canal and inner layer, the spinal dura mater. Between the two layers 
lies the epidural space.
The spinal  canal  is  triangular  in  cross  section.  The Epidural  space is 
widest in the midline posteriorly in the lumbar region, averaging about 5mm. In 
mid thoracic region the distance is 3-5 mm in midline.
BOUNDARIES OF EPIDURAL SPACE:       
Above: The foramen magnum where the periosteal  and the spinal  layers  of 
duramater fuse together.
Below: The sacrococygeal membrane 
Anteriorly: The posterior longitudinal ligament covering the posterior aspect
           of vertebral bodies and the intervertebral discs.
Laterally: Pedicles of the vertebra and the intervertebral foramina.
Ligamentum flavum is an important landmark for technical identification 
of  the  epidural  space.  It  is  composed of  yellow elastic  fibres  disposed in  a 
vertical direction. It connects the upper and lower borders of adjacent lamina. It 
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is thinnest in the cervical region, becoming progressively thicker lower down 
the spine and thickest in the lumbar region.
CONTENTS OF EPIDURAL SPACE:   
1. Dural sac 
2. Spinal nerve roots 
3. Epidural plexus of veins 
4. Spinal arteries
5. Lymphatics 
6.  Fat
31 pairs of spinal nerves with their dural cuff traverse the space on their 
way to intervertebral foramina.
The internal vertebral venous plexus draining both cord and canal lies 
mainly, in the anterolateral parts of epidural space. These veins have no valves 
–  VALVELESS,  VERTICAL,  VERTEBRAL  VEINS  OF  BATSON.  It  has 
segmental  connections  at  all  levels.  Through  this  network,  increased  intra- 
abdominal and intrathoracic pressures are transmitted to epidural space and the 
epidural  veins  get  distended.  They  connect  pelvic  veins  below  to  the 
intracranial veins above. 
The contents of epidural space lie cushioned in a packing of semi-fluid 
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lobulated fat. The epidural fat constitutes an important pharmacologic space and 
depot for injected local anaesthetic agents. It is one of the three competitors for 
the drugs, other two being central nervous tissue (spinal cord and spinal roots) 
and  blood  vessels.  Drugs  with  high  lipid  solubility  and  lipoprotein  binding 
characteristics will tend to enter the fat phase and remain there for periods of 
time, depending on their pharmacodynamics and on the briskness of local blood 
flow competing for uptake.
The volume of the extradural space is large, compared to the intradural 
volume.  Usual  distance between skin and extradural  space is  4- 5  cm.  This 
epidural  space can be entered posteriorly  at  any level  of spinal  column and 
depending upon the  level  where  it  is  entered,  it  is  called cervical,  thoracic, 
lumbar or sacral epidural.
EPIDURAL PRESSURE:
There are many theories for the presence of negative pressure in epidural 
space: -
1. Cone theory: (Eaton – Lawerence )
Dimpling of dura by needle: The advancing needle dents a cone 
of resilient dura within the unyielding walls of spinal canal.  
2. Transmission theory: (Mc Intosh – Bryce smith)
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Transmission of negative pressure from thorax via paravertebral 
spaces especially in thoracic region
3. Full flexion of back
4. Initial bulge forwards of the yellow ligament in front of the advancing 
needle, followed by its rapid return to the resting position once needle 
has perforated the ligament.
5. Redistribution  of  CSF  in  the  intradural  space  greater  in  recumbent 
position, than in vertical position.
Negative pressure in the extradural space is not the same at all levels and 
in the sacral  canal  it  is  absent.  It  is  readily  recorded in the cervical  and 
thoracic regions when patients were sitting up, but less marked in lumbar 
region. Better negative pressure was obtained in the lumbar region when 
patients were sitting up in a flexed position, for the abdominal contents are 
more  compressed.  The  intra-abdominal  pressure  is  higher  in  the  sitting 
position and this pressure is transmitted to the lumbar epidural space.
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IDENTIFICATION OF EPIDURAL SPACE
Techniques for identification of the epidural space:
1. Sudden lack of resistance to the advancing needle as it leaves the dense 
ligamentum flavum (Pages).
2. Sudden ease  of  injection of  little  air  or  liquid,  from a freely running 
syringe attached to the needle (Sicard, Forestier, Dogliotti) 
3. Withdrawal of hanging drop of saline in the hub of needle (Gutierrez 
sign)
4. In an unconscious patient,  rapid injection of liquid into the extradural 
space  is  accompanied  by  increase  in  rate  &  depth  of  respiration 
(Durran’s sign)
5. Injection of distilled water will cause some discomfort to the patient, if 
placed in epidural space (Lund sign).
Visual aids:
1. Movement of bubble on odom’s indicator
2. McIntosh extradural space indicator
3. McIntosh spring loaded syringe 
4. U tube manometer
5. Aneroid manometer
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6. Zorraquins bulb indicator 
7. Zelenka balloon indicator 
8. Brooks indicator
9. Dawkin’s gravity indicator
10. Auditory devices – sagarnaya 
11. Ultrasonic localization
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PHYSIOLOGY OF PAIN
In  1979,  the  International  Association  for  the  Study  of  Pain  (IASP) 
proposed  a  definition  of  pain  as,  “an  unpleasant  sensory  and  emotional 
experience associated with actual  or  potential  tissue damage or  described in 
terms of such damage”. 
Surgery  produces  local  tissue  damage  with  consequent  release  of 
algesic  substances  (prostaglandins,  histamine,  serotonin,  bradykinin,  5-
hydroxytryptamine and substance-P) and generation of noxious stimuli, that are 
transduced by noiciceptors  and transmitted by Aδ and C nerve fibres to the 
neuraxis. Further transmission is determined by complex modulating influences 
in the spinal cord. Some impulses pass to the anterior and anterolateral horns, to 
provoke segmental reflex responses. Others are transmitted to higher centres, 
via  the  spinothalamic  and  spinoreticular  tracts,  where  they  produce 
suprasegmental and cortical responses. 
Cortical responses in awake, unanaesthetised patients after surgery are 
provoked  by  nociceptive  impulses  reaching  the  highest  brain  center,  where 
complex  systems  concerned  with  integration  and  perception  of  pain  are 
activated.  Apprehension  and  anxiety  may  accompany  pain  resulting  in 
additional hypothalamic stimulation. 
There are 2 components of pain – neurophysiologically mediated sensory 
17
component and an emotional experience. 
There are 2 types of pain: 
1. Physiological pain is a transient sensation due to noxious, mechanical, 
thermal,  chemical  stimulus  each with  a  clearly  defined threshold and 
without causing damage to the nervous system. 
2. Pathological  pain  is an  inflammatory  response  to  tissue  injury  or 
damage to central nervous system with an alteration in perception. Pain 
following surgery is pathological.  
There are 2 major theories of pain: 
1. Specific theory – proposed by Von Frey states that the pain is due to 
stimulation of specific receptors. 
2. Intensive  summation  pattern  theory –  proposed  by  Gold  Scheider 
states that there are no specific pain receptors and any sensory stimulus 
if sufficiently severe would produce pain. 
ORGANISATION OF PAIN PATHWAYS 
     According to the recent theory, pain pathway is organized as follows: 
RECEPTORS: - 
Nociceptive receptors are fine, profusely branched, free nerve endings 
covered by schwann cells with, little or no myelin. They are present in skin, 
viscera and other organs. 
The various nociceptors are
18
1. Cutaneous nociceptors 
They  are  connected  to  small  myelinated  Aδ fibres  with  conduction 
velocities between 5 to 30 metres / second. They form free nerve endings in the 
superficial layer of the dermis with terminations that penetrate in the epidermis. 
These receptors respond particularly well to pinching or squeezing the skin or 
to  pinprick.  Cutaneous  nociceptors  are  also  connected  to  unmyelinated  C 
afferent  fibres  with  conduction  velocities  1.5  meters/second  or  less.  They 
respond  to  noxious  levels  of  mechanical,  thermal  or  chemical  stimuli.  In 
addition,  they  are  sensitive  to  many  pain  producing  substances  such  as 
bradykinin,  capsaicin,  potassium  ions,  histamine,  acetylcholine  and  strong 
acids. So they are known as polymodal nociceptors or C-fibres mechano-heat 
(CMH) nociceptors. 
2. Muscle and joint nociceptors 
 Nociceptors are also described in deep tissues such as muscles, ligaments 
and joints. 
Aδ afferent fibres – respond to chemicals known to cause muscle pain 
such potassium ions, bradykinin or serotonin and to sustained contraction of the 
muscle. 
C – fibres –respond to noxious chemicals and to other noxious stimuli, 
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that produce muscle pain such as, pressure or heat and also muscle pain due to 
contraction under ischemia. 
3. Visceral nociceptors 
They are thought to play a role in signaling of events such as myocardial 
ischemia, irritation of airways, pulmonary congestion, testicular injury, biliary 
and renal colic or labour pain. Most of these are connected to unmyelinated C 
afferent fibres. 
FIRST ORDER NEURONS: -
       Pain signals  are  transmitted from pain receptors  along myelinated A-
delta fibres and unmyelinated C fibres and terminate on cells in the dorsal horn. 
Anatomically  A-delta  fibres  synapse  with  cells  in  laminae  I  and  V  (wide 
dynamic neurons) of the dorsal horn, whereas C fibres synapse with cells in 
laminae II and III, which are also known as the substantial gelatinosa. 
SECOND ORDER NEURONS: -
Cells in laminae I and V of spinal cord are spinothalamic cells, and about 
75%  of  fibres  originating  from  these  cells  cross  to  the  contralateral 
spinothalamic tract. 
Near the thalamus, the spinothalamic tract divides into a lateral portion 
often  called  the  neospinothalamic  tract,  and  a  medial  portion  called  the 
paleospinothalamic tract. 
The  phylogenetically  newer  portion  of  the  spinothalamic  tract 
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(neospinothalamic tract) projects to the posterior portions of the thalamus and is 
considered to be involved in the spatial and temporal aspects of pain perception. 
The  phylogenetically  older  portion  of  the  spinothalamic  tract 
(paleospinothalamic tract) projects to the medial thalamus and is responsible for 
the initiation of unpleasant aspects of pain as well as autonomic responses to 
pain. The paleospinothalamic tract has numerous synapses with the reticular 
formation  of  the  brain  stem,  the  medial  thalamus,  the  periaqueductal  gray 
matter, and the hypothalamus. 
Other  pathways  involved  in  cephalad  transmission  of  pain  impulses 
include the spinocervical tracts, spinoreticular tracts and spinomesenencephalic 
tracts. 
THALAMIC TERMINUS: -
Most of the fibres of the spinothalamic tract  terminate in the nucleus 
ventroposterolateralis  (VPL),  which is  the  major  sensory  relay nucleus.  The 
other  fibres  terminate  in  the  posterior  group  of  nuclei  that  include  nucleus 
venteroposteromedialis,  intralaminar  nuclei,  ventrobasal  complex,  and 
hypothalamic nuclei. 
THIRD ORDER NEURONS: -
 Projections from the thalamus end in three cortical areas, SI II and the 
cingulate gyrus on the side opposite  to the stimulus.  The cingulate gyrus is 
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involved in emotion. C fibres transmit burning and aching types of pain, which 
is consistent with the diffuse projections of these fibres from the thalamus into 
the limbic and subcortical areas. These signals also activate reticular activating 
system. 
Some descending neural pathways exert a modifying effect on incoming 
noxious input. That, such sites existed was predicted by the gate control theory 
of pain. Many such sites,  such as the periaqueductal gray matter,  have high 
concentrations of endogenous opioid neurotransmitters. These areas project to 
the rostroventral medulla and, via the reticulospinal tracts and the dorsal lateral 
funiculus, to laminae I, II and V. Other neurochemicals like norepinephrine and 
serotonin are implicated in these inhibitory or modulatory circuits. 
PERCEPTION OF PAIN      
The threshold of perception of pain is, the lowest intensity of stimulus 
recognized as pain. The conscious awareness or perception of pain occurs when 
the thalamocortical pathway is destroyed. Somatosensory cortex is essential for 
the  accurate  localization,  appreciation  of  intensity  and  other  discriminative 
aspects  of  pain.  Prefrontal  cortex  sub  serves  the  unpleasant  affective  and 
emotional reaction to pain. 
Gate control theory of pain  
Melzack and Wall proposed the gate control theory in 1965. Dorsal horn 
of  the  spinal  cord  may  function  as  a  gate,  controlling  the  subsequent 
transmission of impulses via the spinothalamic tract. The stimulation of large 
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diameter afferent fibres from an area in which pain is initiated inhibits smaller 
pain fibres and reduces pain. The mechanism may be presynaptic inhibition at 
the endings of the primary afferents that transmit pain impulses. 
Modulation of pain transmission via the spinothalamic tract through the 
stimulation of large afferent fibres, excite the inhibitory cells in the lamina II 
and III of dorsal horn, which in turn causes pre and post synaptic inhibition of 
secondary transmission neurons (T cells) in the lamina V of dorsal horn and 
interrupt  pain  pathway.  Conversely,  stimulation  of  small  pain  afferents  (C 
fibres) inhibits the T cells in the excitatory state, thus facilitating transmission 
of pain. 
MODULATION OF PAIN 
Pain impulses traveling via afferent nerves from pain receptors enter the 
dorsal  horn  of  the  spinal  cord  and  at  this  site,  release  excitatory 
neurotransmitters,  such  as  glutamate  or  a  11-aminoacid  peptide  known  as 
substance P.  These  are  necessary  for  further  cephalad transmission of  pain. 
Transmission of pain impulse may be modulated by, activation of descending 
inhibitory pain pathways that pass from brain to the spinal cord. It seems likely 
that a central nervous system substance, possibly endorphins is responsible for 
activating  these  descending  inhibitory  pathways.  Opioid  receptors  in  the 
substantia gelatinosa of the spinal cord probably have substance P containing 
terminals and opioids produce analgesia by inhibiting release of substance P. 
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Furthermore  opioid  binding  sites  and  endorphins  are  present  in  the 
periaqueductal  gray  area  of  the  midbrain,  where  electrical  stimulation  can 
produce  analgesia.  Thus  endorphins  and their  receptors  are  well  situated  to 
function in an endogenous pain suppression system. In addition to endorphins, 
other nonopioid inhibitory neurotransmitters released by descending pathway 
fibres may include serotonin, noepinephrine, and possibly glycine and gamma-
aminobutyric acid. 
Central sensitization or wind up   
Prolonged nociceptive  stimulation  leads  to  hyperexcitability  of  dorsal 
horn  cells  and  increased  cephalad  transmission  resulting  in  increased  pain 
sensation. This is responsible for chronic pain syndromes. 
Descending inhibitory pathways and endogenous pain control mechanisms 
It  extends  from  the  hypothalamus  along  the  periventricular  and 
periaqueductal grey matter, which communicate through dorsolateral funiculus 
to end in the nucleus raphe magnus and locus ceruleus. Stimulation anywhere 
along this tract, releases endogenous opioid like peptides and endorphins, which 
activate  serotoninergic  pathway via  descending reticulobulbar  spinal  system, 
interact with lamina I and II of the dorsal horn and exert analgesia. Another 
descending inhibitory pathway arises from locus ceruleus in pons and projects 
directly  to  the  spinal  cord.  Here,  neurotransmitter  is  noradrenaline  and  this 
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pathway inhibits pain responses in spinal cord by, α2 adrenergic mechanism.
RECENT CONCEPTS: -
Spinal cholinergic anti-nociception 
GABAergic  interneurones  posses  muscarinic  receptors  on  both  axon 
terminals  and  somatodendritic  sites,  that  the  activation  of  these  receptors 
increases  the  excitability  of  inhibitory  interneurones  and  enhances  GABA 
release  in  the  substantia  gelatinosa.  This  GABAergic  inhibitory  system  is 
further controlled by cholinergic neurons located in the deep dorsal horn. Those 
effects  may  be  responsible  for  the  antinociceptive  action  produced  by  the 
intrathecal  administration  of  muscarinic  agonists  and  acetylcholinesterase 
inhibitors. 
Studies  conducted  have  shown  that  spinally  mediated  cholinergic 
antinociceptive response was mediated through, inhibition of the local release 
of  substance P.  The results  of those studies  support  the  role of  endogenous 
spinal  acetylcholine,  in  pain  modification  and  suggest  an  interaction  with 
substance P neurons of the dorsal spinal cord. 
α2 adrenergic agonists like clonidine are thought to produce analgesia, in 
part, by activating spinal acetylcholine release. 
Spinal cholinergic pathways for antinociception may interact with spinal 
opioid and adrenergic nerve tracts. There is now substantial evidence that acetyl 
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cholinesterase  inhibitors  and  muscarinic  receptor  agonists  increase  the  pain 
threshold after spinal administration. A muscarinic interneuron may explain the 
interactions with other neurotransmitters. 
Muscarinic  receptors  are  concentrated  in  the  superficial  layers  of  the 
dorsal horn of the spinal cord, an area of noxious sensory processing and these 
reflect innervation, primarily from cholinergic neurons with cell bodies deep in 
the  neck  of  dorsal  horn.  Spinal  injection  of  cholinergic  agonists  results  in 
analgesia that primarily reflects muscarinic receptor activation. 
Nature of postoperative pain 
After surgery, the patient may complain of pain directly related to the 
site of surgery or coincidentally from other sites. Noxious stimulation, which 
may give rise to pain, can be classified as: 
• Mechanical: Direct trauma to tissues, wound tension, muscle spasm, 
distension of a viscus 
• Chemical: Inflammation, tissue ischemia 
• Thermal 
• Radiation  
 The site of surgery is an important factor in determining the degree of 
pain,  its  localisation  and  duration.  Operations,  which  invade  the  superficial 
tegument (the skin) but do not divide major somatic muscle groups, cause a 
type of  pain described as soreness and dullache,  both very  sensitive to  low 
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concentrations of analgesics. 
Muscle  splitting  laparotomy  approach  causes,  less  postoperative  pain 
than the muscle dividing approach. Any laparotomy, which involves the cutting 
of muscle and tendinous layers, is associated with pain, which is exaggerated by 
movement  especially,  deep  breathing  and  coughing.  It  is  less  amenable  to 
treatment with opioids than the poorly localized, dull aching pain characteristic 
of invasion of the peritoneum. 
Most postoperative pain is related to muscle spasm, which is a defence 
mechanism to minimize movement or distortion of the injured part. Relief of 
muscle spasm by low concentrations of local anaesthetics can be surprisingly 
effective in relieving pain. 
Psychological aspects of pain  
The  preexisting  psychological  state  of  a  patient  may  have  a  strong 
influence on the central processing component of acute pain after surgery. The 
same operation can elicit very different responses from patients, some of who 
will  decline analgesia because they do not feel that it  is  necessary,  whereas 
others may find it impossible to achieve adequate analgesia. 
Physiological effects of postoperative pain     
Sympathoadrenal outflow 
Increase  in  plasma  catecholamines  may  result  in  dysrhythmias, 
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tachycardia  and  hypertension,  which  may  induce  myocardial  ischemia  in 
susceptible  patients,  because  of  increased  myocardial  oxygen  demand  or 
reduced supply. 
Blood coagulation 
Pain activates the coagulation system, platelet aggregation and alters the 
fibrinolytic system. These alterations serve to enhance clotting and may lead to 
postoperative  complications  such  as,  deep  venous  thrombosis,  pulmonary 
embolism and arterial thrombotic events. 
Neuroendocrine stress response  
Increased release of cortisol, aldosterone and ADH, during peri-operative 
period  may  contribute  to  postoperative  hyperglycemia,  oliguria  and  water 
retention. ACTH, glucagons, renin and angiotensin II are the other hormones 
that are increased after postoperative pain perception. 
Pulmonary dysfunction 
Pulmonary dysfunction is noted most commonly, after upper abdominal 
and  thoracic  operations.  Loss  of  lung  volumes  due  to  acute  restrictive 
pulmonary dysfunction (thoracic splinting) may result in relative hypoxemia, 
major atelectasis and pulmonary consolidation. 
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Gastrointestinal effects  
Sympathetic hyperactivity related to pain can cause reflex inhibition of 
gastrointestinal  function  and  leads  to  paralytic  ileus,  nausea,  vomiting  and 
urinary retention. 
Advantages of epidural analgesia in the postoperative pain relief 
1. Reduced sympathoadrenal outflow 
2. Reduced neuroendocrine responses 
3. Reduced incidence of deep venous thrombosis and pulmonary embolism 
as well  as  arterial  thrombotic events  (may be related to an inhibitory 
effect  on  platelet  aggregation  as  well  as  improvement  in  lower  limb 
blood flow). 
4. Improved  postoperative  pulmonary  function  may  be  due  to  early 
ambulation, improved cough reflex and desplinting of the thorax.
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PHARMACOLOGY OF BUPIVACAINE 
Bupivacaine  was  synthesized  by  Bo  af  Ekenstem  in  1957.  Telivuo 
introduced it for clinical use in 1963.  At present, bupivacaine is acknowledged 
as most suitable agent for epidural and intrathecal administration.
Chemistry 
It is an aminoamide type local anaesthetic. It is N- butyl pipecolic 2,6 
dimethyl xylidide hydrochloride. The aromatic ring system gives it a lipophilic 
character. The base is not soluble, but the hydrochloride salt readily dissolves in 
water. It is very stable both to repeated autoclaving and to acids and alkalis, but 
solutions  containing  adrenaline  should  not  be  autoclaved  more  than  twice. 
Commercial bupivacaine is a racemic mixture of both isomers.
Molecular weight - 324 Daltons
Pka -     8.05
Protonation at pH of 7.4 - 80%
Protein binding - 95%
Volume of distribution - 72 litres
t½  (∝) - 2.7 mins
t½ (ß) - 2.8 mins
t½ (γ) - 3.5 hours 
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Clearance - 0.47 litres/min
PHARMACOKINETICS 
Absorption:
Systemic absorption of injected local anaesthetic is, modified by several 
factors,  including  the  site  of  injection,  dosage  and  volume,  addition  of 
vasoconstrictors and pharmacologic profile of the agent itself. Neuronal uptake 
of the drug is presumably enhanced by higher local drug concentration Toxic 
blood concentration not definitely established but approximately 1.5 - 3µg/ml
Distribution:
A  two-compartment  model  can  describe  the  systemic  distribution  of 
local anaesthetics. The rapid disappearance phase is due to uptake by rapidly 
equilibrating tissues (i.e tissues that have high vascular perfusion). The slower 
phase of disappearance from blood is a function of particular compound.
Metabolism and excretion:
Metabolized in the liver by N-dealkylation. The metabolic breakdown 
product pipecolylxylidine, is approximately one-eight as toxic as bupivacaine. 
Pipecolylxylidine  and  unchanged  bupivacaine  are  slowly  excreted  in  about 
equal proportions in urine.
Use of Vasoconstrictors:
Addition of adrenaline does not greatly prolong its effect but reduces its 
toxicity. Peak effects of bupivacaine, are minimally influenced by the addition 
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of  a  vasoconstrictor,  after  injection  into  the  lumbar  epidural  space,  but 
significantly reduces the rate of vascular absorption of this drug, when used for 
peripheral nerve blockade.
PHARMACODYNAMICS: -
Mechanism of action:
Local  anesthetics  prevent  transmission  of  nerve  impulses  (conduction 
blockade) by, inhibiting passage of sodium ions through ion selective sodium 
channels in nerve membranes. When progressively increasing concentrations of 
local  anaesthetic,  are  applied  to  a  nerve  fibre,  the  threshold  for  excitation 
increases, impulse conduction slows, the rate of rise of action potential declines, 
the action potential amplitude decreases and finally the ability to generate an 
action potential is abolished.
Action on nerves:
Different types of nerve fibres differ significantly in their susceptibility 
to  local  anaesthetic  blockade,  on  the  basis  of  size  and  myelination.  Upon 
application of a local anaesthetic to a nerve root, the smaller B (<3 µm) and C 
(0.3-1.2 µm, unnmyelinated) type fibres are blocked first. The small Aδ fibres 
(2-5µm) are blocked next. Thus pain fibres are blocked first, other sensations 
disappear next and motor function is blocked last.
32
Effect of fibre diameter 
Local anaesthetics preferentially block small fibres because; the distance 
over which such fibres can passively propagate an electrical impulse (related to 
the  space  constant)  is  shorter.  The  local  anaesthetic,  to  halt  impulse 
propagation,  must  block three  successive  Nodes  of  Ranvier  in  a  myelinated 
fibre. Myelinated nerves tend to become blocked before unmyelinated nerves of 
the same diameter. For this reason, the preganglionic B fibres may be blocked 
before the smaller unmyelinated C fibres.
Effect of firing frequency:
Blockade by local anaesthetics is more marked at, higher frequencies of 
depolarization and with longer depolarization. Sensory fibres especially, pain 
fibres (Aδ and C fibres) have a high firing rate and a relatively long action 
potential duration (up to 5 ms). Motor fibres fire at a slower rate and have a 
shorter action potential duration (<0.5ms). Aδ and C fibres are smaller diameter 
fibres that participate in high frequency pain transmission. They therefore are 
blocked sooner with low concentration of local anaesthetic, than are the A∝ 
fibres.
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SIDE EFFECTS:
1. Allergic reactions:
Allergic reactions are rare despite, the frequent use of these drugs. An 
allergic reaction may also be due to methylparaben or similar substances used 
as preservatives in commercial preparation.
2. Systemic toxicity:
Systemic  reactions  to  local  anaesthetics  primarily  involve  the  central 
nervous system and the cardiovascular system. This is due to excess plasma 
concentration of the drug.
a. Central Nervous system toxicity    
  The  initial  symptoms  of  local  anaesthetic  induced  CNS  toxicity  are 
feelings of lightheadedness and dizziness,  followed frequently by visual  and 
auditory disturbances like difficulty in focusing and tinnitus. Objective signs of 
CNS toxicity are usually excitatory and include shivering, muscle twitching and 
tremors  initially  involving,  muscles  of  the  face  and  distal  parts  of  the 
extremities. Ultimately, generalized convulsions of a tonic-clonic nature occur. 
In some patients, CNS depression without a preceding excitatory phase is seen 
particularly if other CNS depressant drugs have been administered.
b. Cardiovascular system toxicity:
Bupivacaine  depresses  the  rapid  phase  of  depolarization  (Vmax)  in 
purkinje fibres and ventricular muscles to a greater extent than, Lidocaine does. 
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Rate  of  recovery  from  a  use-dependent  block  is  also  slower.  So,  there  is 
incomplete restoration of  Na+ channel availability  between action potentials, 
particularly at high rates, leading to arrythmogenicity.
High blood levels prolong conduction time through various parts of the 
heart.  Extremely  high  concentrations  also  depress  spontaneous  pacemaker 
activity resulting in sinus bradycardia and arrest. There is also a dose-dependent 
negative ionotropic action. The CC/CNS dose ratio for bupivacaine 3.7 ± 0.5
Treatment 
No medications are uniformly effective in facilitating resuscitation from 
bupivacaine  induced  cardiac  arrest  or  severe  ventricular  tachycardia.  Basic 
principles of securing the airway, providing oxygenation and ventilation and 
instituting chest compression, should be emphasized. Epinephrine, bretylium, 
amrinone and phenytoin have been tried.
Uptake of epidural bupivacaine into the cerebrospinal fluid is 30.6µg/ml, 
90minutes after epidural injection of 150ml (30 ml of 0.5% solution) with, 1 in 
2,00,000 epinephrine. CSF concentration of this order (0.03 mg/ml) is relatively 
low,  compared  to  the  levels  of  other  agents  found  in  CSF  after  epidural 
injection. Very high lipid solubility and protein affinity of bupivacaine suggest 
that, a considerable portion of the drug will distribute itself rapidly out of CSF 
phase into the neuraxis and the CSF concentration will not necessarily reflect 
the actual degree of neural uptake that is taking place.
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Clinically  efficacy  of  bupivacaine  is  little  affected  by  presence  or 
absence of adrenaline
But, differences do occur in the quality of blockade and vascular uptake. 
So, epinephrine is clearly advantageous. Marked increases in blood levels of 
bupivacaine have been observed, when epinephrine is omitted.
As with all local anaesthetics, ideal practice should avoid solutions of 
low pH premixed with epinephrine and instead, epinephrine should be added 
freshly in accurately measured amounts to produce a concentration of 5µg/ml, 
just prior to use. In this way, pH is usually several units more alkaline than 
premixed solutions and therefore,  more likely to have faster onset  from the 
greater proportion of nonionized lipid soluble base.
EPIDURAL BUPIVACAINE: -
Bupivacaine  is  extensively  used  for  lumbar  epidural  blockade 
particularly, when prolonged analgesia is required. It is reputed to be four times 
as potent as lignocaine, so that 0.5% bupivacaine solution is roughly equivalent 
to 2% lignocaine.
For  single  shot  epidural,  the  maximum  safe  dose  is  about  2mg/kg. 
Analgesia in postoperative period lasts  for 3-5 hours.  Onset is within 10-20 
minutes when, 0.25% - 0.75% solution used.
For prolonged analgesia 50mg doses can be repeated every 2-3 hours, a 
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maximum dose without adrenaline of 320 mg and with adrenaline of 500 mg 
could be given with safety. Clinically occurring blood levels of bupivacaine are 
usually;  well  below those likely to produce toxic symptoms and it  is  a  less 
cumulative drug than lignocaine or mepivacaine.     
CLINICAL PREPARATIONS:
Bupivacaine is manufactured in concentrations of 0.25% and 0.5% for 
epidural use.
0.5% Bupivacaine
This was the strength originally selected for surgical anaesthesia and the 
drug performs reasonably well in this concentration. Latency is similar to 0.5% 
tetracaine. Latency of onset is 5.8 minutes – 18.2 minutes.
Dose requirements decline form about 6.75mg per segment at 20yrs to 
3.8mg per segment at 80years; average at 40years 5.8mg per segment. 
Quality of motor blockade is relatively less when compared to, effective 
sensory  analgesia.  However,  intensity  of  sensory  block  in  L5  and  S1  is 
unimpressive and quality of analgesia in these segments is not usually sufficient 
for comfort, during operations on lower leg and ankle in conscious patients.
2-segment regression time is 196 ± 31 minutes with 1/2,00,000 epinephrine.
0.25% Bupivacaine
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Latency  is  slow,  motor  block  negligible  and  quality  of  surgical 
anaesthesia in adults is barely adequate for satisfactory operating conditions. 
However, this dilute solution with epinephrine is ideally suited for relief of pain 
in labour and for postoperative pain relief.
0.125% Bupivacaine 
Used mainly for labour analgesia.
Uses of Bupivacaine:- 
1. Local infiltration 
2. Peripheral nerve blocks
3. Spinal anaesthesia 
4. Epidural anaesthesia
5. Labour analgesia  
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PHARMACOLOGY OF NEOSTIGMINE
The action of acetylcholine released from autonomic and somatic motor 
nerves are terminated by enzyme destruction of  the  molecule.  Hydrolysis  is 
accomplished by the action of acetylcholinesterase, a protein with a molecular 
weight of about 3,20,000 Daltons, which is present in high concentrations in the 
cholinergic synapses. 
Neostigmine  is  an  anticholinesterase  most  often  administered  by  the 
anaesthesiologists, to facilitate the speed of recovery from the skeletal muscle 
effects produced by non-depolarising muscle relaxants. 
MECHANISM OF ACTION 
Enzyme inhibition   
Neostigmine inhibits the breakdown of acetylcholine by virtue of it being 
hydrolyzed  by  acetylcholinesterase,  indirectly  increasing  the  amount  of 
acetylcholine available to compete with the nondepolarizing agent, thereby re-
establishing neuromuscular transmission. In this process, acetylcholinesterase is 
carbamylated,  and  it  cannot  hydrolyze  acetylcholine.  Carbamylated 
acetylcholinesterase has a halftime of 15-30 minutes. The clinical duration of 
cholinesterase inhibitor effect however is probably most influenced by the rate 
of drug disappearance from the plasma. Difference in duration of action can be 
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overcome by dosage adjustments. 
In  the  absence  of  nondepolarizing  neuromuscular  blocking  drugs, 
administration  of  an  anticholinesterase  drug  may  produce  spontaneous 
contractions (fasciculations) of skeletal muscles. These presynaptic effects are 
abolished by a  small  dose of  nondepolarizing neuromuscular  blocking drug, 
suggesting that acetylcholine receptors are involved. 
Direct effects at neuromuscular junction  
If dose greater than that administered clinically, anticholinesterase drugs 
produce neuromuscular blockade probably due to an excess of acetylcholine be 
resulting in desensitization (endplate no longer responsive to acetylcholine). 
Physical structure 
Neostigmine is  a  quarternary ammonium derivative  of  physostigmine. 
The carbamate moiety provides covalent bonding to acetylcholinesterase. The 
quarternary ammonium group renders the molecule lipid insoluble so that  it 
cannot pass through the blood brain barrier. 
PHARMACOKINETICS    
After  a  single  bolus  dose,  the  plasma  concentration  of  neostigmine 
reaches a peak and decreases rapidly during the first 5-10 minutes. The volume 
of distribution is 0.7 to 1.4 liters/kg, and the elimination half time is 77 minutes. 
The  clearance  is  9.2ml/kg/min,  which  is  much  greater  than  the  glomerular 
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filtration rate. 
Neostigmine does not penetrate lipid cell membrane layers such as the 
gastrointestinal tract or blood brain barrier. 
Neostigmine has an onset  of  action of 7-11 minutes.  The duration of 
action  of  anticholinesterase  drugs  is  governed  largely  by  the  rate  of 
disappearance of these drugs from the plasma. For example, the half time of the 
carbamylated enzyme (15-30 minutes) is much shorter than the elimination half 
times of the anticholinesterase drugs (60-120minutes). 
Renal clearance  
Anticholinesterase  drugs  are  actively  secreted  into  the  lumens  of  the 
renal  tubules.  Renal  clearance  accounts  for  approximately  50%  of  the 
elimination  of  neostigmine.  As  a  result,  the  elimination  halftime  is  greatly 
prolonged by renal failure. 
Metabolism  
Mainly metabolized in kidney. The principal metabolite of neostigmine 
is 3-hydroxyphenyl trimethylammonium, which has approximately one-tenth of 
the antagonistic activity of the parent compound. 
PHARMACODYNAMICS 
The pharmacological effects of anticholinesterase drugs are predictable 
and  reflect  the  accumulation  of  acetylcholine  at  muscarinic  and  nicotinic 
41
cholinergic receptor sites. Muscarinic cholinergic effects, such as bradycardia, 
salivation, miosis, and hyperperistalsis are evoked by lower concentration of 
acetylcholine  than  are  required  for  the  production  of  effects  at  autonomic 
ganglia and the neuromuscular junction. 
Cardiovascular effects 
The cardiovascular effects of anticholinesterase drugs reflect the effects 
of  accumulated  acetylcholine  at  the  heart  (vagal  effects),  blood  vessels, 
autonomic ganglia, and postganglinonic cholinergic nerve endings. Bradycardia 
and/or bradyarrythmias such as nodal and ventricular escape beats and asystole 
may  occur.  Bradycardia  most  likely  reflects  slowing  of  the  conduction  of 
cardiac impulses through the atrioventricular node. Decreases in systemic blood 
pressure  that  may accompany the accumulation of acetylcholine presumably 
reflect the decrease in systemic vascular resistance, although the coronary and 
pulmonary circulations may manifest an opposite response.   
Gastrointestinal and genitourinary tract
Neostigmine  enhances  gastric  fluid  secretion  by  parietal  cells  and 
increases the motility of the entire gastrointestinal tract, particularly the large 
intestine. Neostigmine may increase the incidence of postoperative nausea and 
vomiting  even  when  administered  with  atropine.  The  lower  portion  of  the 
oesophagus is stimulated by neostigmine, resulting in a beneficial increase in 
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tone and peristalsis in patients with achalasia.
Salivary gland
Neostigmine augments production of secretory glands that are innervated 
by  post-ganglionic  cholinergic  fibres.  Such  glands  include  the  bronchial, 
lacrimal, sweat, salivary, gastric, intestinal and pancreatic glands. 
Smooth muscle 
Smooth  muscle  fibres  of  the  bronchioles  and 
ureters  are  contracted.  Cholinergic  stimulation 
results  in  bronchoconstrictron  and 
anticholinesterase  drugs  have  the  potential  to 
increase the airway resistance.
Eye
Miosis, inability to focus for near vision and a decrease in intraocular 
pressure occurs due to muscarinic actions.
CLINICAL USES OF NEOSTIGMINE
The principal clinical uses are:
1. Antagonist assisted reversal of neuromuscular blockade.
2. Treatment of myasthenia gravis
3. Postoperative  analgesia   –  Intrathecal  administration  of  neostigmine 
inhibits the metabolism of acetylcholine-released form the spinal cord. 
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Acetylcholine is one of more than 25 neurotransmitters that participate in 
spinal cord modulation of pain procession. In this regard, intrathecal and 
epidural neostigmine produce postoperative analgesia without producing 
ventilatory  depression,  characteristic  of  neuraxial  opioids,  although 
nausea is common.
Neurotoxicity  does  not  accompany  intrathecal  or  epidural  administration  of 
commercially  available  neostigmine  preparations  containing  paraben 
preservatives (Eisenach et al 1997).
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ASSESSMENT OF PAIN
Pain is a combination of severe discomfort, fear, autonomic changes, 
reflex activity and suffering. The intensity of pain can be measured in two 
ways:
1. Assessment by observers
2. Self reporting
In children, both these methods are used and in adults, the self-reporting 
method is most commonly used.
Assessment by observers
In children, the most commonly used scoring systems include
1. The Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS)
2. Pediatric objective pain scale
The  arterial  blood pressure,  crying,  movement,  agitation  and posture  are 
taken for scoring in these two systems.
Self – reporting methods
These  are  most  commonly  used  in  adult  patients  and  depend  on  the 
information given by the person in pain.
 They are:
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1. Visual Analogue Pain Scale
2. Henry Prince Pain Scale
3. CPR Pain Scoring
4. Facial Rating Scale
5. MC Gill Pain Questionnaire (MPQ)
In the present study, the Visual Analogue Pain Scale was used and hence 
it is discussed in detail here.
VISUAL ANALOGUE PAIN SCALE (VAS)
VAS  provides  simple,  efficient  and  minimally  intrusive  method  of 
assessment  of  pain  intensity,  which  has  been  used  widely  in  clinical  and 
research settings where a quick assessment of pain is required and to which a 
numerical value can be assigned.
The  most  common  VAS  consists  of  a  10cm  horizontal  (Huskisscon 
1983) or a vertical (Sriwatanakul et al 1983) line with the two endpoints labeled 
‘no pain’ and ‘worst pain ever’. The patient is required to place a mark on the 
10cm line at a point with corresponds to the level of pain intensity he or she 
presently feels. The distance in centimeters from the lower end of the VAS to 
the patient’s mark is used as a numerical index of the severity of pain.
Advantages of VAS
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1. Its easiness.
2. Minimal intrusiveness
3. Provided that adequately clear instructions are given to the patient, its 
conceptual simplicity.
Disadvantages of VAS
1. It assumes that pain is a unidimensional experience.
2. It eliminates the possibility that each pain has unique qualities.
VAPS – Quality of Analgesia
0.1 Excellent
2.4 Good
5.6  Fair
7.8  Slight 
9-10 No relief
Duration of analgesia
Duration of analgesia was defined as that period from the time of giving 
the epidural analgesia, till the patient’s first requirement of systemic analgesics 
due to slight pain at rest. Supplementary analgesia was given when the pain 
score was more than 5 in the VAS.
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REVIEW OF LITERATURE
1. Hartwig P et al and Gillberg P et al studied the effects of intrathecal 
acetylcholinesterase  inhibitors  and  muscarinic  receptor  agonists  in  pain 
threshold in rats.  There is now substantial evidence that acetylcholinesterase 
inhibitors  and muscarinic  receptor  agonists  increase  the  pain threshold  after 
both  systemic  and  spinal  administration.  In  rats,  physostigmine  gave  a 
significant dose-dependent increase in latency times in the tail immersion test 
following intrathecal administration. The effect was antagonized with atropine. 
Neostigmine  gave  more  prolonged  latencies  as  did  the  muscarinic  receptor 
agonist carbachol.  Spinal  cholinergic pathways for antinociception interacted 
with the spinal opioid and adrenergic nerve tracts. No cross – tolerance to the 
selective alpha 2-adrenoreceptor agonist guanfacine or to morphine was seen in 
rats  tolerant  of  spinal  carbachol  antinociception.  The  mechanism  of  spinal 
cholinergic  antinociception  is  not  known but  a  muscarinic  interneuron  may 
explain the interactions with other neurotransmitters.
2.  Baba  H,  Okamoto  M  and  Kohno  T  studied  the  muscarinic 
facilitation of GABA release in substantia gelatinosa of the rat spinal dorsal 
horn. Blind patch clamp recording were made form substantia gelatinosa (SG) 
neurons in the adult rat spinal cord slice to study the mechanisms of cholinergic 
modulation of  GABAergic inhibition.  In  the majority  of  SG neurons  tested, 
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carbachol (10µG) increased the frequency (677% of control)  of spontaneous 
GABAergic Inhibitory Post Synaptic Currents (IPSCs). The effect of carbachol 
on  spontaneous  IPSCs  was  mimicked  by  neostigmine,  suggesting  that 
GABAergic interneurones are under tonic regulation by cholinergic systems. 
All  the  effects  of  carbachol  and neostigmine were  antagonized  by  atropine, 
while pirenzepine (100 nM), methoctramine (1µg) and hexahydrosiladifenidol 
hydrochloride, p-fluoroanalog (100nM) had no effect. Focal stimulation of deep 
dorsal horn, but not dorsolateral funiculus, evoked a similar increase in IPSC 
frequency to that evoked by carbachol and neostigmine. They have suggested 
that  GABAergic  interneurones  possess  muscarinic  receptors  on  both  axon 
terminals  and  somatodendritic  sites,  that  the  activation  of  these  receptors 
increases  the  excitability  of  inhibitory  interneurones  and  enhance  GABA 
release in SG and that the GABAergic inhibitory system is further controlled by 
cholinergic  neurons  located  in  the  deep  dorsal  horn.  These  effects  may  be 
responsible  for  the  antinociceptive  action  produced  by  the  intrathecal 
administration of muscarinic agonists and acetylcholinesterase inhibitors.
3. Tan PH, Chai YY and Lo Y compared the postoperative analgesic 
efficacy and safety of intrathecal (IT) neostigmine and IT morphine in patients 
undergoing  total  knee  replacement  under  spinal  anesthesia.  Sixty  patients 
scheduled  for  elective  total  knee  replacement  under  spinal  anesthesia  were 
randomly divided into three equal groups  who received IT 0.5% hyperbaric 
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bupivacaine  15mg  with  either  normal  saline  0.5  ml,  neostigmine  50µg  or 
morphine 300  µg.  Results:   There was no significant difference in maximal 
level of sensory block among the three groups. The morphine group had a later 
onset of post surgical pain and longer time to first rescue analgesics than the 
neostigmine group (P <0.05). Overall 24-hr VAS pain scores were significantly 
higher in the saline group Vs the morphine and neostigmine groups (P <0.05). 
Motor block lasted significantly longer in the neostigmine group than in the 
morphine and saline groups (P <0.05). The incidence of adverse effects was 
similar  in  the  neostigmine  and  morphine  groups  except  for  pruritis  (70%) 
occurring more frequently in the morphine group than in the neostigmine and 
saline group (0%; P <0.05). CONCLUSIONS: IT neostigmine 50 microgram 
produced postoperative  analgesia  lasting  about  seven hours  with  fewer  side 
effects and better satisfaction rating than IT morphine 300µg.
4. Gurun Ms. Et al Leinbach R et al conducted studies on the safety of 
glucose  and  paraben-containing  neostigmine  for  intrathecal  administration. 
Initial  toxicity  testing  of  neostigmine  for  intrathecal  (IT)  injection  was 
performed with preservative  – free  isobaric  solution,  yet  currently  available 
formulations  contain  the  preservatives  methyl  and  propylparaben  and  are 
usually  mixed with glucose  to  yield hyperbaric  solutions.  Since it  has  been 
proposed that preservative and hyperbaricity increase the risk of neurotoxicity 
after  IT  injection,  they  examined  the  safety  of  chronically  administered  IT 
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neostigmine containing these additives in sheep and rats. Spinal cord histologic 
examination in both species revealed fibrosis and inflammation secondary to 
the catheter without evidence of neuronal damage. These studies support the 
safety of paraben- and glucose containing IT neostigmine.
5.  Lauretti  GR,  de  Oliveira  R,  Reis  MP,  Juliao  MC, Pereira  NL 
conducted a study to define the analgesic effectiveness of epidural neostigmine 
co  administered  with  lignocaine  and  side  effects  in  patients  after  minor 
orthopedic  procedures.  After  0.05-0.1  mg/kg  intravenous  midazolam 
premedication,  patients  were  randomized into  four  groups  to  receive  20 mg 
intrathecal  bupivacaine  plus  epidural  lignocaine  (85mg)  with  saline  (control 
group));  1  microgram/kg  epidural  neostigmine  (1microgram  group);  2 
microgram/kg epidural neostigmine (2 microgram group); epidural neostigmine 
4 microgram/kg (4 microgram group). Results: The visual analog scale score at 
first rescue analgesic and the incidence of adverse effects were similar among 
groups (P > 0.05). The time (min ± SD) to first rescue analgesic was as follows: 
control group: 205 ± 48; 1-microgram group: 529 ± 314; 2-microgram group: 
504  ± 284;  4-microgram  group:  547  ± 263  (P  <  0.05).  The  analgesic 
consumption (number of  intramuscular  diclofenac injections  [mean,  25th 75th 
percentile]) in 24 h was as follows: control groups: 3 (3 or 4); 1-microgram 
group:1 (1 or 2);  2-microgram group : 2 (1 or 2);   4-microgram 2 (1 or 3) 
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(P < 0.05). The 24-h pain visual analog scale score (cm ± SD) that represents 
the overall impression for the last 24 hour was as follows: control group: 5  ± 
1-6; 1-microgram group 1.6 ± 1.8; 2-microgram group: 1.4 ± 1.6; 4-microgram 
group:  2.2  ± 1.9  (P  < 0.005).  The incidence of  adverse  effects  was  similar 
among groups (P > 0.05). They concluded that epidural neostigmine (1,2 or 4 
microgram / kg) in lignocaine produced dose – independent analgesic effect 
(approximately 8h) compared to the control group (approximately 3.5 h) and a 
reduction in postoperative rescue analgesic consumption without increasing the 
incidence of adverse effects.
6. Alpha 2-Adrenergic agonists are thought to produce analgesia, in part, 
by activating spinal acetylcholine release. Hood et al and Mallak et al studied 
the  interaction  between  intrathecal  neostigmine  and  epidural  clonidine  for 
analgesia  and  side  effects  in  humans.  The  combination  of  neostigmine  and 
clonidine resulted in an additive enhancement of analgesia, but no enhancement 
of each drug’s side effects, and a reduction in clonidine induced hypotension. 
Neostigmine injected into subjects in the lateral position diminished clonidine – 
induced reductions in blood pressure and plasma norepinephrine. Hence, their 
results  support  enhancement  of  alpha  2-  adrenergic  analgesia  by  intrathecal 
neostigmine, but do not demonstrate synergy, as observed in animals. Lack of 
enhancement of side effects suggests this combination may be clinically useful.
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7.  Nakayama  et  al  evaluated  the  effects  of  epidurally  administered 
neostigmine  on  pain  after  abdominal  hysterectomy.  45  ASA  I  status  adult 
patients received general and epidural anaesthetic. At the end of surgery, they 
received  epidural  bupivacaine  10mg  with  saline  (n=15),  5  microgram/kg 
neostigmine or 10 microgram / kg neostigmine. If patient wants additional pain 
relief,  50mg diclofenac  suppository  was  given.  The  time  to  first  diclofenac 
administration was significantly longer (P <0.05) in the 10 microgram/kg group 
than in the control  group or  5-microgram /  kg groups.  They concluded that 
epidural  neostigmine  10  microgram/kg  with  bupivacaine  provides  a  longer 
duration of analgesia than does bupivacaine with or without 5 microgram/kg 
after abdominal hysterectomy.
8. Lauretti GR, de Oliveira R et al  postoperative analgesia by intra – 
articular  neostigmine  1  microgram/kg  or  500  micrograms  or  epidural 
neostigmine  1  microgram/kg.  They  concluded  that  although  peripheral 
neostigmine 1 microgram/kg did not result in postoperative analgesia, the same 
dose applied epidurally results in over 5 hours of analgesia similar to five-fold 
dose applied peripherally. The results suggest that epidural neostigmine has a 
greater analgesic efficacy than peripherally applied neostigmine.
9.  Owen  MD,  Ozsarac  O,  Sahin  S,  Uckunkaya  N,  Kaplan  N, 
Magunaci  studied the addition of low dose clonidine and neostigmine on the 
duration of analgesia for labour. Forty – five healthy parturients in active labor 
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were randomized to receive a 2 ml intrathecal dose of one of the following 
dextrose – containing solutions using the combined spinal epidural technique 
(1) bupivacaine 2.5mg and fentanyl 125 microgram (BF) l (2) BF plus clonidine 
30 microgram (BFC); or (3) BFC plus neostigmine 10 microgram (BFCN). Pain 
scores,  block  characteristics,  maternal  vital  signs,  Apgar  scores,  maternal 
satisfaction,  and  side  effects  were  similar  among groups  except  for  nausea, 
which was significantly greater in the BFCN group (P <0.05 as compared with 
BFC).  The addition of clonidine and neostigmine significantly increased the 
duration of analgesia form intrathecal bupivacaine – fentanyl during labour, but 
neostigmine  caused  more  nausea.  Although  serious  side  effects  were  not 
observed in this study, safety must be further addressed before the routine use 
of multiple intrathecal drugs is advocated. 
10.  Tan  P-H  et  al  studied  the  efficacy  and  safety  of  intrathecal 
neostigmine  for  the  relief  of  pain  for  patients  having  undergone  inguinal 
herniorrhaphy.  Sixty  men  undergoing  elective  inguinal  herniorrhaphy  with 
spinal anaesthesia were randomly allocated into three groups of 20 each, group 
I received intrathecal tetracaine 15 mg, group II received intrathecal tetracaine 
15mg  with  neostigmine  50  micrograms  and  group  III  received  intrathecal 
tetracaine 15mg with neostigmine 100 micrograms. Onset of anaesthesia was 
significantly faster for groups II and III; motor block was greatly prolonged for 
group III patients with an average of 6.4hr, compared with 4.1hr for group II. 
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Group III patients also showed later onset of post surgical pain; lower overall 
24hr Visual Analogue Score and prolonged time to first rescue analgesia than 
did  group  II  patients.  They  concluded  that  intrathecal  neostigmine  at  50 
micrograms or 100 micrograms enhanced that onset of tetracaine anaesthesia 
and provided analgesia for 6-9h although, increased incidences of prolonged 
motor blockade and nausea or vomiting were noted.
11. Hood DD, Eisenach JC, Tuttle R studied the safety on intrathecal 
neostigmine methyl sulfate in humans. 28 healthy volunteers were divided into 
two groups; the first 14 volunteers received neostigmine 500-750 microgram 
caused  severe  nausea  and  vomiting.  Neostigmine  by  either  method  of 
administration reduces visual analogue pain scores to immersion of the foot in 
ice water. The study concluded that no dangerous side effects occurred.
12. Kirdemit  P  et  al  compared  the  analgesia  and  side  effects  of 
preemptively used epidural ketamine + bupivacaine, neostigmine + bupivacaine 
and  bupivacaine  alone  on  postoperative  analgesia  after  major  abdominal 
surgery. 30 ASA I/II/III patients undergoing general anaesthesia were selected; 
group N received 0.5mg neostigmine and bupivacaine 25mg epidurally, group 
B received 1ml saline and 25mg bupivacaine epidurally and group K received 
ketamine 50mg and bupivacaine 25mg epidurally 30 minutes before operation. 
All underwent general anaesthesia with thiopentone and vecuronium induction, 
and  were  maintained  with  isoflurane  and  vecuronium.  In  group  N  Visual 
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Analogue  Score  and  total  postoperative  opioid  consumption  was  significant 
lower than in groups K and B they concluded that  pre-emptive neostigmine 
could be a good choice for post operative analgesia.
13.  Lauretti  G R,  Hood DD et  al  reported  a  multicentric,  placebo-
controlled trial, which investigated the effects of 25-75 microgram intrathecal 
neostigmine  on  analgesia  and blood pressure  in  women undergoing  vaginal 
hysterectomy.  92 women scheduled for vaginal hysterectomy were randomized 
to receive an intrathecal injection of 2ml of bupivacaine 0.75% in dextrose with 
either 1ml saline or 25,50, or 75 µg neostigmine. Pain, nausea, haemodynamic 
profile and postoperative morphine use was assessed. The study showed that 
morphine use was reduced by all doses of neostigmine; incidence of nausea was 
greater  in  patients  receiving neostigmine  (61%) than in  those  who received 
saline placebo. No significant change in haemodynamic status was noted in all 
groups. The study concluded that analgesia from intrathecal neostigmine may 
occur at  doses less  than 50  µg and that  neostigmine does not reduce spinal 
bupivacaine induced hypotension.
14. Lauretti GR, Mattos AL, Reis MP, Prado WA studied the effect 
of intrathecal neostigmine for postoperative analgesia after orthopedic surgery. 
60 ASA physical status I and II unpremedicated patients undergoing orthopedic 
surgery  (tibial  or  ankle  reconstruction)  were  given  spinal  anesthesia  in  the 
sitting position,  L3-L4 interspace,  and 4 ml volume,  injected at  a  rate  of  1 
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ml/10sec.  The  control  group  –  (CG) received  15mg hyperbaric  bupivacaine 
0.5%  plus  saline.  The  25  µg  neostigmine  group  (25NG)  received  15mg 
hyperbaric bupivacaine plus 25µg neostigmine; the 50  µg neostigmine group 
(50NG)  received  15  mg  hyperbaric  bupivacaine  plus  50  micrograms 
neostigmine;  and  the  100  µg  neostigmine  group  (100NG)  received  15mg 
hyperbaric  bupivacaine  plus  100  µg  neostigmine.  Times  to  first  rescue 
analgesics,  analgesia,  and adverse effects at constant intervals were assessed 
using the 10cm visual analog scale (VAS). Intrathecal neostigmine produced a 
dose-independent reduction in the postoperative rescue analgesic consumption 
(p<0.0001).  The  time  to  first  rescue  analgesics  was  similar  among  groups 
(p<0.05), and the overall 24-hour VAS pain scores were lowest for patients who 
had spinal neostigmine (p<0.02). The 100NG group had the highest incidence 
of  postoperative nausea and vomiting of  all  the  groups (p<0.05).  The study 
concluded intrathecal neostigmine produced a dose-independent analgesia and a 
dose dependent incidence of adverse effects with the doses studied. 
15. S. P. Chittora et al studied the effect of neostigmine as an additive 
to lignocaine for postoperative analgesia in intrathecal and epidural anaesthesia. 
Neostigmine  50  microgram  added  to  5%  lignocaine  given  intrathecally 
prolonged duration of analgesia from 123.3 ± 14.8 minutes in lignocaine group 
to 368.1 ± 145.4 minutes in lignocaine + neostigmine. Nausea in 25%, vomiting 
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in 20%, hypotension and sweating in 5% of total cases was observed. Nausea 
and vomiting were severe in neostigmine group compare to plain lignocaine 
group.  The  neostigmine  100  microgram  epidurally  provided  comparable 
prolongation of analgesia (355 ± 105 minutes) to intrathecal neostigmine group 
(368.1 ± 145.4)  
16.  De-Rosa  et  al  have  shown  significant  increase  in  postoperative 
analgesia  from  85  ± 10  minutes  to  270  ± 43  minute  in  bupivacaine  – 
neostigmine group compared to bupivacaine alone.
17.   Klamt  et  al  found  that  spinal  neostigmine  with  bupivacaine  as 
effective  as  morphine  and  significantly  prolonged  the  duration  of  analgesia 
compared with saline. It was 4.5 ± 1, 15.3 ± 7.1 and 10.7 ± 4.3 hours for saline, 
morphine  (100  microgram)  and  neostigmine  (100  microgram)  groups 
respectively.
18. Rudra A et al found that caudal administration of bupivacaine with 
the  addition  of  neostigmine  resulted  in  superior  analgesia  compared  with 
bupivacaine alone. Requirement of initial analgesic to provide pain relief in the 
postoperative  period  was  after  7.6  ± 5.4  hours  of  surgery  in  40  children 
belonging  to  bupivacaine  group.  However,  the  requirement  of  initial  pain 
relieving agent was after 19.0 ± 4.2 hours of surgery in 40 children, those who 
received caudal bupivacaine plus neostigmine.
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19. Abdulatif M, Turan A, et al in their studies with 2 microgram/kg of 
neostigmine  have  not  mentioned any  behavioral  or  histological  evidence  of 
neurotoxicity  from  epidural  administration  of  neostigmine  with  methyl  and 
propylparaben as preservatives in a glucose containing solution. 
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                    METHODOLOGY
Study Design: Double blind randomized clinical trial 
This  prospective  clinical  study  was  conducted  at  Government 
Rajaji Hospital. Madurai, after obtaining Ethical Committee Clearance, in 50 
patients. Informed consent was obtained from each patient after explaining the 
procedure in detail.
The patients posted for elective lower abdominal surgeries were chosen 
at random. ASA grade I patients of both sex with, age ranging from 18 to 75 
years were included in the study. Pregnant and lactating females, patients with 
spinal deformities, local skin sepsis, bleeding disorders and psychiatric illness 
were excluded from the study.
Pre-anaesthetic evaluation 
A complete physical examination was done to detect any abnormality in 
heart, lung, abdomen and central nervous system. Assessment was also done to 
exclude any local disease, which may interfere with anaesthesia.
Routine biochemical, haematological investigations, ECG, and chest X-
ray were taken. Baseline measurements of respiratory rate, breath holding time 
and SpO2 were done. Patients were explained about the 10-point visual analog 
scale.
The 50 patients were allocated into 2 groups 
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- Group  B  receiving  20  ml  of  0.5%  bupivacaine with 
adrenaline 5microgram/ml + 1 ml of normal saline and 
- Group  BN  receiving  20  ml  of  0.5%  bupivacaine with 
adrenaline  5  microgram/ml  +  100  microgram  of 
neostigmine in 1 ml of normal saline.
Anaesthetic Technique 
No premedication was given to these patients. 
The  following  resuscitative  measures  were  kept  ready  before 
administering epidural anaesthesia.
   Boyle’s machine with oxygen supply.
Laryngoscope and appropriate size endotracheal tubes.
Suction apparatus 
Vasopressors and other emergency drugs.
Contents of the epidural tray were: sponge holding forceps, sterile gauze 
pieces, bowl with antiseptic solutions, sterile towels, 24 gauge needle and 5 ml 
syringe,  16  gauge  Tuohy  needle,  16  gauge  epidural  catheter,  10  ml  glass 
syringe with freely moving piston, 2% lignocaine vial, 0.5% bupivacaine vial 
injection adrenaline, injection neostigmine.
After positioning the patients in the right lateral decubitus position, a 16 
gauge Tuohy needle was used to perform the midline epidural block in L2-L3 or 
L3-L4 space, with “ loss of resistance to air ” technique being used to identify 
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the epidural space. A 16 gauge epidural catheter was inserted upto 5 cms length, 
directed  cephalad  and  fixed  in  place.  Aspiration  was  done  to  rule  out 
subarachanoid or intravascular placement of the catheter. A test dose of 2 ml of 
1.5%lignocaine  with  5µg/ml  of  adrenaline  was  given  through  the  catheter. 
Later, the total dose of the local anaesthetic was given through the catheter and 
the patient was placed in supine position.
The level of sensory blockade was assessed every 2 minutes. The time 
taken for the onset of sensory block at T10 and the time taken for the maximum 
level of sensory block was noted down. The time taken for onset of grade 3 
motor block was also noted.
The pulse rate, blood pressure and respiratory rate were monitored every 
5 minutes, throughout the surgery. Hypotension was defined as ≥20% decrease 
in systolic blood pressure from the baseline value and bradycardia was defined 
as  pulse  rate  ≤60/min.  Treatment  plan  for  hypotension  was,  rushing  of 
intravenous fluids and administration of injection ephedrine 6mg intravenous 
boluses.  Treatment  plan  for  bradycardia  was  administration  of  injection 
atropine sulphate intravenously.  Continuous SpO2 monitoring was done. The 
patients were also observed for other complications of neostigmine like nausea, 
vomiting bradycardia, drowsiness, sedation, increased secretions and intestinal 
cramps.  The  two-segment  regression  time  and  the  duration  of  surgery  was 
noted. 
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Post Operative Monitoring 
At the  end of  the  surgery,  the  epidural  catheter  was  removed under, 
aseptic precautions and a seal of tincture benzoin was applied. Patients were 
observed in the recovery room for the next 1 hour and sent to the postoperative 
ward where, vital parameters like pulse rate, blood pressure, respiratory rate, 
SpO2 were recorded every 30 minutes for the next 6 hours and hourly thereafter 
till the patient’s first requirement of systemic analgesic medication.  Patients 
were also observed for complications like bradycardia, vomiting, hypotension, 
sedation,  bronchoconstriction,  respiratory  depression  or  abdominal  cramps 
during the surgery and in the postoperative period. 
Although  preservative  free  neostigmine  is  not  associated  with 
neurotoxicity  it  is  no  longer  marketed.  Many  studies  have  established  the 
absence  of  any  behavioral  or  histological  evidence  of  neurotoxicity  from 
epidural  administration  of  neostigmine  with  methyl  and  propyl  paraben  as 
preservatives. Therefore, we believed that the dose of neostigmine with 
methyl  paraben  as  preservative  used  in  our  study  would  not  result  in  any 
neurotoxicity. Neurological sequalae, including persistant paraesthesia, sensory 
or  motor  deficit  and  bowel  or  bladder  dysfunction  were  reviewed  in  the 
subsequent days and outpatient followup.     
The level of consciousness was assessed every 30 minutes and graded 
according to the sedation score (Brian and Ready).
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0 – fully awake
1 – normal sleep
2 – drowsy, arousable on touch
3 – drowsy, arousable to painful stimuli
4 – somnolent.
Duration of analgesia
Duration of analgesia was defined as that period from the time of giving 
the epidural anaesthesia till the patient’s first requirement of systemic analgesic 
medication.  In  this  study,  patients  with  VAS  >  5  were  given  systemic 
supplementary analgesics.
VAS Scoring
Patients were asked to point the intensity of pain on the 10-point visual 
analog scale of pain.  The first  VAS score was noted and the time at  which 
patients request additional systemic analgesics was noted.
RESULTS 
The statistical  analysis  of  the  data  is  presented  as  mean ± standard 
deviation. The two groups were compared by student ‘t’ test and p<0.05 was 
considered as significant.        
OBSERVATIONS AND RESULTS
In the present study, patients who underwent lower abdominal surgeries 
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were divided into two groups.
Group  B  –  Receiving  20ml  of  0.5%  Bupivacaine  with  5µg/ml  of 
adrenaline + 1ml of normal saline.
Group BN – Receiving  20 ml  of  0.5% Bupivacaine  with 5µg/ml of 
adrenaline + 100 µg of neostigmine in 1ml of normal saline.
Patients  in  both  groups  were  comparable  in  age,  sex  and  weight 
distribution. All were ASA grade I patients. 
None  of  the  patients  had  narcotic  premedication  or  intra-operative 
analgesic supplementation.
Age Distribution 
The  minimum  and  maximum  age  in  group  B  was  18  and  74  years 
respectively.  The minimum and maximum age in group BN was 18 and 65 
years respectively. The mean age of patients (in years), in group B was 46.32 ± 
13.51 and group BN patients was 42.24 ± 13.22. ‘p’ value – 0.282 ( p > 0.05, 
which is not statistically significant). The details are given in Table – 2.
Weight distribution 
The  minimum and  maximum weight  in  group  B  was  40  and  70  kg 
respectively.  The minimum and maximum weight  in group BN was 40 and 
80kg respectively. The mean weight of the patients (in kilograms) in  group B 
was 51 ± 6.82 and in group BN was 53.08 ± 8.71. ‘p’ value – 0.346 (p > 0.05, 
which is not statistically significant). The details are given in Table -2.
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Time of onset of block at T10
In  both groups,  the  minimum and maximum time taken for  onset  of 
sensory blockade at T10 was 5 minutes and 10 minutes respectively, with a mean 
of 7.28  ± 1.30 minutes in group B and 6.56  ± 1.44 in group BN. ‘p’ value- 
0.073. (p > 0.05, which is not statistically significant). The details are provided 
in Table – 3. 
Time for maximum level of sensory block
The  time  for  the  maximum  level  of  sensory  block  in  group  B  was 
between 8 - 18 minutes with mean of 13.28  ± 2.22 minutes and in group BN 
was between 10 – 20 minutes with a mean of 14.16 ± 2.71 minutes. ‘p’ value – 
0.158 (p > 0.05, which is not statistically significant). The details are provided 
in Table – 3. 
Maximum level of sensory block    
In  both  groups  the  maximum  level  of  sensory  block  attained  was 
between T4 – T6 with a mean of T4.72±0.93 in group B and T4.32±0.74  in group BN (p 
> 0.05, which is not statistically significant).
Time for Grade 3 motor block 
In group B the grade 3 motor block was achieved with a mean of 16.6 ± 
4.04  minutes  and  in  group  BN  it  was  with  the  mean  of  17.96  ± 3.8 
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minutes. ‘p’ value – 0.24 (p > 0.05, which is not statistically significant). The 
details are provided in Table – 3. 
Two segment regression time 
In  group B the  two segment  regression time  was in  the  range of  80 
minutes to  135 minutes with a mean of 111.8 ± 12.9 minutes and in  group BN 
it was in the range of 90 minutes to 180 minutes with a mean of 123.6 ±  20.43 
minutes.  ‘p’ value – 0.035 (p < 0.05, which is statistically significant).  The 
details are shown in Table – 4.
Duration of surgery 
In group B, the mean duration of surgery was 111 ± 19.14 minutes and 
group BN it was 117.8 ± 31.16 minutes. ‘p’ value – 0.413 (p > 0.05, which is 
not statistically significant). The details are shown in Table – 4.
DURATION OF POSTOPERATIVE ANALGESIA  
In group B, the minimum duration of analgesia was 240 minutes and 
maximum duration was 330 minutes with a mean of 286.8  ±  23.44 minutes; 
standard  error  of  4.68  minutes  and  group  BN  the  minimum  duration  of 
analgesia was 360 minutes  and maximum duration was 720 minutes with a 
mean of  515.8  ± 89.69  minutes;  standard  error  17.93  minutes.  ‘p’  value  – 
0.0001   (p  <<  0.05  which  is  statistically  highly  significant).    The  95% 
confidence interval for group B was 277.12  to  296.47 minutes and in group 
BN it was 478.77  to  552.82 minutes. The details are represented in Table – 5. 
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Vitals    
Oxygen  saturation which  was  measured  by  pulse-oximetry  was 
maintained above 97% in all patients in both the groups.
Respiratory rate was  > 10/min in all of the patients.
           Heart rate and mean arterial pressure was comparable in both groups.
Complications 
Hypotension occurred intra-operatively in 3 patients in group B (12%) 
and 2 patients in group BN (8%), p > 0.05, which is not statistically significant.
Vomiting occurred in the recovery room in 2 patients in group B (8%) 
and  4  patients  in  group  BN  (16%),  p  >  0.05,  which  is  not  statistically 
significant.
No patients developed bradycardia, which was taken as a heart rate less 
than 60/min. 
No patients developed complications like, bronchoconstriction sedation, 
respiratory  depression or  abdominal cramps during and after  the  surgery,  in 
both the groups.
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DISCUSSION
In  the  recent  years,  many  drugs  have  been  combined  with  local 
anesthetics in the epidural route for providing postoperative pain relief. Opioids 
have  been  successfully  used  for  this  purpose  but  they  have  their  own side 
effects like nausea, vomiting, respiratory depression and pruritis.
Hence  many  adjuvants  like  neostigmine,  ketamine  and  clonidine  are 
being  used  in  the  epidural  route  in  combination  with  local  anaesthetics  for 
providing  postoperative  analgesia.  The  present  study  was  to  evaluate  the 
efficacy  of  neostigmine,  along  with  bupivacaine  in  the  epidural  route  for 
postoperative analgesia.
Mechanism of action of neostigmine in the spinal cord
Baba et al and Kohno et al studied the muscarinic facilitation of GABA 
release in substantia gelatinosa of the rat spinal dorsal horn. They concluded 
that  GABAergic  interneurones  possess  muscarinic  receptors  on  both  axon 
terminals  and  somatodendritic  sites,  that  the  activation  of  these  receptors 
increases  the  excitability  of  inhibitory  interneurones  and  enhances  GABA 
release in the substantia gelatinosa and that the GABAergic inhibitory system is 
further controlled by cholinergic neurons located in the deep dorsal horn. These 
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effects  may  be  responsible  for  the  antinociceptive  action  produced  by  the 
intrathecal  administration  of  muscarinic  agonists  and  acetylcholinesterase 
inhibitors.
Smith  et  al  has  concluded  from  his  studies  that  there  is  a  role  of 
endogenous  spinal  acetylcholine  in  pain  modification  and  suggested  an 
interaction with substance P neurons of the dorsal spinal cord.
Hood et al proposed that α2 adrenergic agonists are thought to produce 
analgesia, in part, by activating spinal acetylcholine release.
Hartwig  et  al  postulated  that  spinal  cholinergic  pathways  for 
antinociception interacted with the spinal opioid and adrenergic nerve tracts. 
There  is  now  substantial  evidence  that  acetylcholinesterase  inhibitors  and 
muscarinic receptor agonists increase the pain threshold after both systemic and 
spinal administration. The mechanism of spinal cholinergic antinociception is 
not known but a muscarinic interneuron may explain the interactions with other 
neurotransmitters.
Eisenach et al  proposed that muscarinic receptors are concentrated in 
the superficial layers of the dorsal horn of the spinal cord, an area of noxious 
sensory  processing,  and  these  reflect  innervation  primarily  from cholinergic 
neurons with cell bodies deep in the neck of the dorsal horn. Spinal injection of 
cholinergic agonist results in analgesia that primary affects muscarinic receptor 
activation.
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         Seybold VS et al studied the existence of muscarinic receptors, both M1 
and M2, in laminae II and III of the spinal cord autoradiographically. 
Tuttle et al  Proposed analgesia by cholinesterase inhibitors depend on 
degree  of  spinal  cholinergic  tone  in  some  species  and  the  tonic  spinal 
cholinergic activity in normal human is adequate for neostigmine to produce 
meaningful analgesia alone.
Rudra A. et al  has concluded that  Neostigmine an anticholinesterase 
inhibitor may cause an accumulation of ACh at the muscarinic receptors in the 
dorsal horn when entered into CSF. Thus, increased spinal levels of ACh may 
augment antinociceptive effects as  a result  of axonal conduction block from 
epidural bupivacaine. A potent advantage of central neuraxial neostigmine is 
that,  it  may  counteract  local  anaesthetic  induced  hypotension  by  inhibitory 
effect  on  the  sympathetic  nerve  activity.  In  the  current  study,  the  observed 
perioperative  haemodynamic  stability  with  the  use  of  bupivacaine  plus 
neostigmine mixture supports this contention.
COMPARISION OF RESULTS 
There were no significant differences in the time taken for the onset of 
sensory block at T10, time taken for grade 3 motor block, the maximal level of 
sensory block and the time taken to achieve maximum level of sensory block, 
between the two groups.
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Hence, neostigmine had no effect on the speed of onset of sensory block, 
which is similar to the findings of Bone H.G et al. But, this is contrary to the 
findings of Tan P.H et al who showed that intrathecal neostigmine produces 
faster  onset  of  anaesthesia.  This  may  be  because,  they  had  used  50µg 
neostigmine  with  3cc  of  0.5% bupivacaine  intrathecally  but,  in  our  present 
study 100µg of neostigmine with 20cc of 0.5% bupivacaine epidurally.  The 
larger  volume  of  the  drug  used  for  epidural  administration  has  diluted  the 
100µg of neostigmine used. This and the dural cuff must have acted as barriers, 
to the diffusion of neostigmine into the spinal cord and spinal nerve roots 
Also, neostigmine had no effect on the speed of onset of motor block.
           The two segment regression time was delayed in the neostigmine group 
by an average of 11.8 ± 7.53 minutes, which was clinically significant ‘p’value- 
0.035. p <0.05,which is statistically significant.
           The incidence of hypotension in the neostigmine group was comparable 
to  the  control  group.  Vomiting  occurred  in  16% of  patients  in  neostigmine 
group compared to 8% in control group but it was not statistically significant. 
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The  duration  of  postoperative  analgesia  was  enhanced  significantly, 
when neostigmine was added to bupivacaine in the epidural space. The mean 
duration of postoperative analgesia in the bupivacaine group was 286.8 ± 23.44 
minutes  and  in  the  bupivacaine  +  neostigmine  group  was  515.8  ± 89.69 
minutes.  The  duration  of  post  operative  analgesia  in  neostigmine  group  is 
prolonged by 229 ± 66.25 minutes which was clinically significant. The p value 
is 0.0001, p <<< 0.5, which is statistically highly significant.
The results correlate favourably with the studies conducted by, Lauretti 
GR et al and de Oliveira R et al who studied the effect of three different doses 
of  epidural  neostigmine  co-administered  with  bupivacaine  for  postoperative 
analgesia,  Nakayama  et  al  who  studied  the  analgesic  effect  of  epidural 
neostigmine after abdominal hysterectomy, Lauretti GR et al and Perez MV 
et al who studied the postoperative analgesia of epidural neostigmine following 
knee surgery and  Rudra A et al who studied the analgesic effect  of caudal 
neostigmine with bupivacaine for post-op analgesia and have concluded that the 
administration  of  neostigmine  in  the  epidural  space  along  with  a  local 
anaesthetic produces good postoperative analgesia.
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CONCLUSION 
The study was done to evaluate the efficacy of epidurally administered 
neostigmine  along  with  bupivacaine  for  postoperative  pain  relief  in  lower 
abdominal surgeries  and to evaluate the merits  and demerits  of  neostigmine 
administered epidurally.
The conclusion is that  the epidural administration of neostigmine in 
the dose of 100 µg along with 0.5% bupivacaine with adrenaline 5  µg/ml 
prolongs  the  duration  of  postoperative  analgesia  significantly,  with  no 
serious side-effects and does not have any effect on the time taken for the onset 
of sensory and motor blockade. 
          So, NEOSTIGMINE a commonly available drug could be safely used to 
provide  effective  post-operative  pain  relief  for  patients  undergoing  lower 
abdominal surgeries. Hence, NEOSTIGMINE would prove as a cost- effective 
adjuvant  for  local  anaesthetics  and  will  also  prolong  the  duration  of 
postoperative  analgesia  considerably  and  significantly,  without  producing 
serious side effects.  
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PROFORMA
DEPARTMENT OF ANESTHESIOLOGY
MADURAI MEDICAL COLLEGE
MADURAI
Comparative evaluation of epidural bupivacaine with neostigmine and 
epidural bupivacaine alone in lower abdominal surgeries for postoperative 
analgesia
Name: Age/Sex: Address: I.P.No:
Diagnosis: Surgery: D.O.S. Unit: 
Anaesthesiologist: Surgeon: 
Pre anaesthetic assessment Pre operative investigations 
General condition : Urine-Albumin, Sugar & Deposits: 
Weight : Hb% :
CVS : Bleeding Time :
RS : Clotting Time :
Pulse : Blood Urea :
BP : Blood Sugar :
Spines : Serum Creatinine :
Airway : Blood Grouping :
ASA status : Chest X ray :
ECG :
Premedication:
Drug: Dose: Route: Time:
Technique of Anaesthesia: Position:
Space: Approach: Needle: Catheter 
Drugs administered: Bupivacaine         Neostigmine       Volume 
of drug: 
Time of Administration: Time of onset of block at T10: 
Maximum level of sensory block: Time for grade 3 motor block:
Time to attain maximum level of sensory block:    
Two segment regression time: Duration of surgery: 
INTRA OPERATIVE MONITORING 
Time (in 
minutes
)
Level 
of 
block
Pulse 
rate
Blood 
pressure
Respiratory 
rate SPO2
Level of 
consciousness
Complications 
(if any)
POSTOPERATIVE MONITORING  
Time 
(in 
hours)
VAS Pulse rate
Blood 
pressure
Respiratory 
rate
Level of 
consciousness
Complications 
(if any)
Duration of analgesia (in minutes):
COMPLICATIONS (if any)
Nausea 
Vomiting 
Bradycardia 
Hypertension 
Sedation 
Abdominal cramps 
Increased secretions   
